Thrombin Generation Test in Patient With Liver Cirrhosis

NCT02484534 | Completed

• 1 other identifier: EMC62-14
• Study Type: observational
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

Cirrhotic patients are patients with high morbidity and mortality, it is very important for determining the prognosis of these patients. The importance increases when these patients waiting for a liver transplant. The Model for End-Stage Liver Disease (MELD) is a reliable measure of mortality risk in patients with end-stage liver disease. It is used as a disease severity index to help prioritize allocation of organs for transplant. MELD uses the patient values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. Blood tests that we use today in daily practice to evaluate the coagulation system (PT, PTT) do not check actually the functioning of the system, but examine the level of clotting factors and therefore only verify that the side of Anticoagulant of the equation and not the side of the procoagulant . To examine the coagulation system function tests have been developed, One of them is the thrombin generation. The purpose of the trial is to determine whether thrombin generation test can be a prognostic indicator in patients cirrhosis.

Conditions

Cirrhosis

Keywords

Coagulation Factor; cirrhosis

Outcome Measures

Primary Outcomes (1)

• Complications of cirrhosis.

  Complications of cirrhosis, such as ascites, bleeding Varicose veins, encephalopathy or thrombosis of the portal vein.

  3 month.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients (men and women) who are hospitalized in internal and surgical wards with a diagnosis of cirrhosis of the liver.

You may qualify if:

• Cirrhosis patient MELD ( Model For End-Stage Liver Disease) above 12

You may not qualify if:

• Pregnant women

Sponsors & Collaborators

• HaEmek Medical Center, Israel: lead

Study Sites (1)

Haemek medical center

Afula, Israel

Location

MeSH Terms

Conditions

Fibrosis

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: dr

Study Record Dates

• First Submitted: December 21, 2014
• First Posted: June 29, 2015
• Study Start: February 26, 2015
• Primary Completion: December 9, 2015
• Study Completion: January 18, 2017
• Last Updated: August 10, 2017

Record last verified: 2017-08

Locations

IL (1)